Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib

Cancer Science

Volumn 106, Issue 5, 2015, Pages 567-575

  Ishijima, Naoki ^a   Kanki, Keita ^a   Shimizu, Hiroki ^a   Shiota, Goshi ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

AMPK; Combination therapy; Hepatocellular carcinoma; Retinoic acid; Sorafenib

Indexed keywords

CASPASE 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PERETINOIN; PROTEIN BAX; RETINOIC ACID; RNA; SMALL INTERFERING RNA; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE; TAMIBAROTENE; (2E,4E,6E,10E)-3,7,11,15-TETRAMETHYL-2,4,6,10,14-HEXADECAPENTAENOIC ACID; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BAX PROTEIN, HUMAN; BENZOIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; GLUCOSE TRANSPORTER 1; NICOTINAMIDE; RETINOID; SLC2A1 PROTEIN, HUMAN; TETRALIN DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; ENZYME ACTIVATION; GENE REPRESSION; GENETIC ANALYSIS; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOCHONDRION; PRIORITY JOURNAL; UPREGULATION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ADENOSINE TRIPHOSPHATE; AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BENZOATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE TRANSPORTER TYPE 1; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; RETINOIDS; TETRAHYDRONAPHTHALENES; TRETINOIN;

EID: 84929703353     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12633     Document Type: Article

References (44)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
3. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
4. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029-33.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
6. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-46.
7. Kuhajda FP. AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int J Obes (Lond) 2008; 32: S36-41.
8. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95.
9. Wald N, Boreham J, Bailey A. Serum retinol and subsequent risk of cancer. Br J Cancer 1986; 54: 957-61.
10. Larsson SC, Bergkvist L, Näslund I, Rutegård J, Wolk A. Vitamin A, retinol, and carotenoids and the risk of gastric cancer: a prospective cohort study. Am J Clin Nutr 2007; 85: 497-503.
11. Toniolo P, Van Kappel AL, Akhmedkhanov A, Ferrari P, Kato I, Shore RE. Serum carotenoids and breast cancer. Am J Epidemiol 2001; 153: 1142-7.
12. Michaud DS, Feskanich D, Rimm EB, Colditz GA, Speizer FE, Willett WC. Intake of specific carotenoids and risk of lung cancer in 2 prospective US cohorts. Am J Clin Nutr 2000; 72: 990-7.
13. Schenk JM, Riboli E, Chatterjee N et al. Serum retinol and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2009; 18: 1227-31.
14. Yuan JM, Gao YT, Ong CN, Ross RK, Yu MC. Prediagnostic level of serum retinol in relation to reduced risk of hepatocellular carcinoma. J Natl Cancer Inst 2006; 98: 482-90.
15. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer 2001; 1: 181-93.
16. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene 2004; 328: 1-16.
17. Yanagitani A, Yamada S, Yasui S et al. Retinoic acid receptor alpha dominant negative form causes steatohepatitis and liver tumors in transgenic mice. Hepatology 2004; 40: 366-75.
18. Tsuchiya H, Akechi Y, Ikeda R et al. Suppressive effects of retinoids on iron-induced oxidative stress in the liver. Gastroenterology 2009; 136: 341-50.
19. Tsuchiya H, Ikeda Y, Ebata Y et al. Retinoids ameliorate insulin resistance in a leptin-dependent manner in mice. Hepatology 2012; 56: 1319-30.
20. Muto Y, Moriwaki H, Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. N Engl J Med 1999; 340: 1046-7.
21. Shimizu M, Sakai H, Shirakami Y et al. Acyclic retinoid inhibits diethylnitrosamine-induced liver tumorigenesis in obese and diabetic C57BLKS/J- +(db)/+Lepr(db) mice. Cancer Prev Res (Phila) 2011; 4: 128-36.
22. Kim BJ, Ryu SW, Song BJ. JNK- and p38 kinase-mediated phosphorylation of Bax leads to its activation and mitochondrial translocation and to apoptosis of human hepatoma HepG2 cells. J Biol Chem 2006; 281: 21256-65.
23. Blomhoff R, Blomhoff HK. Overview of retinoid metabolism and function. J Neurobiol 2006; 66: 606-30.
24. Shimizu M, Takai K, Moriwaki H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci 2009; 100: 369-74.
25. Takagi K, Suganuma M, Kagechika H et al. Inhibition of ornithine decarboxylase induction by retinobenzoic acids in relation to their binding affinities to cellular retinoid-binding proteins. J Cancer Res Clin Oncol 1988; 114: 221-4.
26. Pettersson F, Dalgleish AG, Bissonnette RP, Colston KW. Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. Br J Cancer 2002; 87: 555-61.
27. Pettersson F, Colston KW, Dalgleish AG. Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells. Pancreas 2001; 23: 273-9.
28. Nakagawa T, Shimizu M, Shirakami Y et al. Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells. Cancer Lett 2009; 273: 250-6.
29. Amann T, Maegdefrau U, Hartmann A et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 2009; 174: 1544-52.
30. Liu Y, Cao Y, Zhang W et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther 2012; 11: 1672-82.
31. Kitamura K, Hatano E, Higashi T et al. Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol 2011; 55: 846-57.
32. Miao P, Sheng S, Sun X, Liu J, Huang G. Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapy. IUBMB Life 2013; 65: 904-10.
33. Sheng SL, Liu JJ, Dai YH, Sun XG, Xiong XP, Huang G. Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma. FEBS J 2012; 279: 3898-910.
34. Le A, Cooper CR, Gouw AM et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010; 107: 2037-42.
35. Weinberg F, Chandel NS. Mitochondrial metabolism and cancer. Ann N Y Acad Sci 2009; 1177: 66-73.
36. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40: 294-309.
37. Cardaci S, Filomeni G, Ciriolo MR. Redox implications of AMPK-mediated signal transduction beyond energetic clues. J Cell Sci 2012; 125: 2115-25.
38. Capano M, Crompton M. Bax translocates to mitochondria of heart cells during simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated protein kinases. Biochem J 2006; 395: 57-64.
39. Xi X, Han J, Zhang JZ. Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J Biol Chem 2001; 276: 41029-34.
40. Gonda K, Tsuchiya H, Sakabe T et al. Synthetic retinoid CD437 induces mitochondria-mediated apoptosis in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2008; 370: 629-33.
41. Zhang W, Konopleva M, Ruvolo VR et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia 2008; 22: 808-18.
42. Kurosu T, Ohki M, Wu N, Kagechika H, Miura O. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res 2009; 69: 3927-36.
43. Chi SW. Structural insights into the transcription-independent apoptotic pathway of p53. BMB Rep 2014; 47: 167-72.
44. Liedtke C, Lambertz D, Schnepel N, Trautwein C. Molecular mechanism of Mitomycin C-dependent caspase-8 regulation: implications for apoptosis and synergism with interferon-alpha signalling. Apoptosis 2007; 12: 2259-70.